| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Rous-Whipple Award Lecture |
From the Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri
Abstract
As Americans live longer, degenerative skeletal diseases, such as osteoporosis, become increasingly prevalent. Regardless of cause, osteoporosis reflects a relative enhancement of osteoclast activity. Thus, this unique bone resorptive cell is a prominent therapeutic target. A number of key observations provide insights into the mechanisms by which precursors commit to the osteoclast phenotype and how the mature cell degrades bone. The osteoclast is a member of the monocyte/macrophage family that differentiates under the aegis of two critical cytokines, namely RANK ligand and M-CSF. Tumor necrosis factor (TNF)-
also promotes osteoclastogenesis, particularly in states of inflammatory osteolysis such as that attending rheumatoid arthritis. Once differentiated, the osteoclast forms an intimate relationship with the bone surface via the vß3 integrin, which transmits matrix-derived, cytoskeleton-organizing, signals. These integrin-transmitted signals include activation of the associated proteins, c-src, syk, Vav3, and Rho GTPases. The organized cytoskeleton generates an isolated microenvironment between the cell’s plasma membrane and the bone surface in which matrix mineral is mobilized by the acidic milieu and organic matrix is degraded by the lysosomal protease, cathepsin K. This review focuses on these and other molecules that mediate osteoclast differentiation or function and thus serve as candidate anti-osteoporosis therapeutic targets.
This article has been cited by other articles:
 |
|
 |
|
  H Tilg, A R Moschen, A Kaser, A Pines, and I Dotan Gut, inflammation and osteoporosis: basic and clinical concepts Gut, May 1, 2008; 57(5): 684 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bai, R. Kopan, W. Zou, M. J. Hilton, C.-t. Ong, F. Long, F. P. Ross, and S. L. Teitelbaum NOTCH1 Regulates Osteoclastogenesis Directly in Osteoclast Precursors and Indirectly via Osteoblast Lineage Cells J. Biol. Chem., March 7, 2008; 283(10): 6509 - 6518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Dass and P. F.M. Choong Zoledronic acid inhibits osteosarcoma growth in an orthotopic model Mol. Cancer Ther., December 1, 2007; 6(12): 3263 - 3270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. KIM, H. ZHAO, H. KITAURA, S. BHATTACHARYYA, J. A. BREWER, L. J. MUGLIA, F. PATRICK ROSS, and S. L. TEITELBAUM Glucocorticoids and the Osteoclast Ann. N.Y. Acad. Sci., November 1, 2007; 1116(1): 335 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Aubin, R. Bouillon, T. A. Guise, and I. R. Reid Meeting Report from the 17th Scientific Meeting of the International Bone and Mineral Society: June 24-29, 2007 in Montreal, Quebec, Canada IBMS BoneKEy, November 1, 2007; 4(11): 299 - 313. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Andrade Jr., T.A. Silva, G.A.B. Silva, A.L. Teixeira, and M.M. Teixeira The Role of Tumor Necrosis Factor Receptor Type 1 in Orthodontic Tooth Movement J. Dent. Res., November 1, 2007; 86(11): 1089 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Rodeo, S. Kawamura, C. B. Ma, X.-h. Deng, P. S. Sussman, P. Hays, and L. Ying The Effect of Osteoclastic Activity on Tendon-to-Bone Healing: An Experimental Study in Rabbits J. Bone Joint Surg. Am., October 1, 2007; 89(10): 2250 - 2259. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
